Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. - Dimopoulos, M. A.; Voorhees, P. M.; Schjesvold, F.; Cohen, Y. C.; Hungria, V.; Sandhu, I.; Lindsay, J.; Baker, R. I.; Suzuki, K.; Kosugi, H.; Levin, M.-D.; Beksac, M.; et al. (New England Journal of Medicine, 2025)